TIDMOBD
RNS Number : 5028W
Oxford BioDynamics PLC
18 April 2023
Oxford BioDynamics Plc
Oxford BioDynamics Plc
( " OBD " or the " Company " and, together with its
subsidiaries, the " Group " )
PDMR Dealing / Grant of Share Options
18 April 2023 - Oxford, UK - Oxford BioDynamics Plc (AIM: OBD),
a biotechnology company developing precision medicine tests for
immune health based on the EpiSwitch(R) 3D genomics platform,
announces that it has granted a total of 863,561 options over its
ordinary shares of 1 pence each ("Ordinary Shares"), to certain
Group employees, including 733,561 options to Chief Executive
Officer, Dr Jon Burrows. The options were granted under the
Company's 2016 Employee Share Option Plan with an exercise price of
15.6p per share.
One-third of the options granted to Dr Burrows will vest and
become exercisable on each of 23 March 2024, 23 March 2025 and 23
March 2026. Vested options will remain exercisable up to and
including the tenth anniversary of the date of grant.
Following this grant, Dr Jon Burrows, holds options over
Ordinary Shares and is interested in Ordinary Shares as
follows:
Total number Ordinary Shares held
of options over
Ordinary Shares
Number % of current
issued share
capital
-------- --------------
Jon Burrows 2,623,714 300,000 0.2%
----------------- -------- --------------
The information set out below is provided in accordance with the
requirements of the UK Market Abuse Regulation.
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Jon Burrows
-------------------------- ---------------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Director/PDMR
-------------------------- ---------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ---------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Grant of share options
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) 733,561 Ordinary Shares at an exercise price
of 15.6 pence per share
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 17 April 2023
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital Tel: +44 (0)20 7408 4090
Nominated Adviser and Broker
Stephane Auton
John More
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Rozi Morris / OxfordBioDynamics@instinctif.com
Adam Loudon
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit .
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFETSFIDLIV
(END) Dow Jones Newswires
April 18, 2023 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024